Keynotes
Sophie Veldhuijzen van Zanten, Nuclear medicine physician, Erasmus Medical Center, Rotterdam, The Netherlands, s.veldhuijzenvanzanten@erasmusmc.nl:
Braintumor PET - PSMA - theranostics/diagnostics (exact title TBD)
Santiago Cepeda Chafla, Neurosurgeon, Rio Hortega University Hospital, Valladolid, Spain, cepeda_santiago@hotmail.com:
Predicting Regions of Local Recurrence in Glioblastomas
(NB! Not confirmed) Krzystof Kilian, Heavy Ion Laboratory, University of Warsaw, kilian@slcj.uw.edu.pl: -Title TBD
(NB! Not confirmed) Dr. Sandrine Huclier-Markai, ARRONAX GIP, Nantes, Frankrike, sandrine.huclier@subatech.in2p3.f: – Title TBD
Joyce van Sluis, Technical physician and postdoctoral researcher, University Medical Center Groningen, j.van.sluis@umcg.nl
PET and pharmacokinetic modeling
André H. Dias, MD, PhD, Aarhus University Hospital, andre.dias@auh.rm.dk
Whole-body parametric imaging
Early Career Researchers
Henrik Herrebrøden – 1 hour lecture or 2-3 hour workshop - confirmed
Stress management in demanding careers
Nelofer Syed, is a Senior Research Fellow and Principle Investigator of the John Fulcher Molecular Neuro-oncology Laboratory at Imperial College London. She is also the co-lead of the Brain Tumour Research Centre of Excellence at Imperial College.
The main focus of her research program is to interrogate the altered metabolism of primary brain tumours in particular glioblastoma, using epigenetic and omics based approaches to identify new metabolic therapies for this hard to treat cancer. The research strategy is to use these metabolic approaches to overcome the immunosuppressive tumour microenvironment and enhance the effectiveness of immunotherapies standard of care. Recent work in her lab on arginine deprivation and the ketogenic diet has revealed some exciting and very important findings for glioblastoma patients. She has demonstrated that these metabolic therapies potentiate the effects of radiation to achieve complete tumour eradication with concomitant increase in survival in pre-clinical orthotopic models. The effects of arginine deprivation and the ketogenic diet on tumour metabolism and its immune microenvironment is under intense investigation in Dr Syed’s laboratory to further understand the mechanistic basis for these findings and discover additional metabolic targets.
Oliver Kiß is organic chemist by training. After obtaining his PhD in Medical Sciences from the University of Groningen (The Netherlands), he worked as radiochemist at the Peter MacCallum Cancer Centre in Melbourne (Australia) and at the German Cancer Research Center (dkfz) in Heidelberg (Germany). Besides his function as Radiopharmaceutical Chemist at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) he is a member of "Group 14 Radiopharmaceutical Preparations” at the European Directorate for the Quality of Medicines and Healthcare (EDQM) in Strasbourg (France), member of the “Working Group Radiopharmaceuticals" at the Federal Institute for Drugs and Medical Devices (BfArM) in Bonn (Germany), a former member of the Radiopharmacy Committee and current member of the Policy and Regulatory Affairs Committee of the European Association of Nuclear Medicine (EANM). His focus lies now on translational radiopharmaceutical chemistry.
Prof. dr. Albert D. Windhorst was trained as a medicinal chemist and currently holds the chair of radiopharmaceutical chemistry at the department of Radiology and Nuclear Medicine at Amsterdam UMC. His research is focused on radionuclide production, radiochemistry methods, design and evaluation of radiopharmaceuticals and translation towards clinical research, with focus on oncology and neurology. He has established Good Manufacturing Practice (GMP) production of radiotracers at his institute (the first academic GMP facility in Europe), in order to facilitate clinical research. Several new PET radiotracers have been developed from preclinical towards clinical research under his supervision and in close collaboration with clinical researchers of Amsterdam UMC. Notably, [11C]erlotinib, [11C]R116301, [11C]docetaxel, [11C]nintedanib, [11C]phenytoin, [11C]sorafenib, [11C]osimertinib [18F]afatinib, [11G]MOM, [18F]fluoro-PEG-folate, [18F]PK209, [11C]SMW139. His research group comprises 36 FTE, amongst which are 2 staff scientists, 2 post-docs and 7 PhD students. In addition he is editor-in-chief of Nuclear Medicine & Biology, past-president and fellow of the Society of Radiopharmaceutical Sciences and is member of the executive committee of the European Society for Molecular Imaging as treasurer.